Hsbc Holdings PLC Sells 11,034 Shares of Simulations Plus, Inc. $SLP

Hsbc Holdings PLC cut its holdings in Simulations Plus, Inc. (NASDAQ:SLP) by 52.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,109 shares of the technology company’s stock after selling 11,034 shares during the period. Hsbc Holdings PLC owned 0.05% of Simulations Plus worth $244,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Fifth Third Bancorp boosted its holdings in Simulations Plus by 33.8% in the 1st quarter. Fifth Third Bancorp now owns 1,485 shares of the technology company’s stock valued at $36,000 after purchasing an additional 375 shares during the period. Tower Research Capital LLC TRC boosted its holdings in Simulations Plus by 42.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,575 shares of the technology company’s stock valued at $72,000 after purchasing an additional 764 shares during the period. US Bancorp DE boosted its holdings in Simulations Plus by 15.6% in the 1st quarter. US Bancorp DE now owns 6,576 shares of the technology company’s stock valued at $161,000 after purchasing an additional 889 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Simulations Plus in the 1st quarter valued at $210,000. Finally, Savvy Advisors Inc. bought a new position in Simulations Plus in the 1st quarter valued at $249,000. 78.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on SLP shares. Zacks Research raised shares of Simulations Plus to a “hold” rating in a report on Tuesday, August 12th. KeyCorp cut shares of Simulations Plus from an “overweight” rating to a “sector weight” rating in a research report on Tuesday, July 15th. BTIG Research lowered their price objective on shares of Simulations Plus from $41.00 to $25.00 and set a “buy” rating on the stock in a research report on Monday, July 7th. JMP Securities restated a “market perform” rating on shares of Simulations Plus in a research report on Wednesday, June 18th. Finally, Craig Hallum lowered their price objective on shares of Simulations Plus from $45.00 to $36.00 and set a “buy” rating on the stock in a research report on Friday, June 13th. Four equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Simulations Plus currently has an average rating of “Moderate Buy” and a consensus target price of $26.50.

Simulations Plus Stock Down 1.8%

Shares of NASDAQ:SLP opened at $14.12 on Friday. The stock has a market cap of $284.24 million, a PE ratio of -4.48 and a beta of 0.85. The company’s fifty day moving average is $14.61 and its 200 day moving average is $23.48. Simulations Plus, Inc. has a 52 week low of $12.39 and a 52 week high of $37.67.

Simulations Plus (NASDAQ:SLP) last issued its earnings results on Monday, July 14th. The technology company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.19. The company had revenue of $20.36 million for the quarter, compared to analysts’ expectations of $22.83 million. Simulations Plus had a negative net margin of 78.63% and a positive return on equity of 11.62%. The firm’s revenue was up 9.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.27 EPS. Sell-side analysts anticipate that Simulations Plus, Inc. will post 1.09 EPS for the current year.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.